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Introduction
The uterus, the organ in which the embryo grows, is composed of 
three layers, the uterine endometrium, the myometrium composed 
of smooth muscle and a serious membrane enveloping the uterus. In 
general, the term uterine tumor refers to an epithelial malignant tumor 
of the uterus, which is roughly classified as a tumor of the uterine cervix 
or the uterine body. Because of the prevalence of screening, uterine 
cervix cancer is decreasing in incidence, and usually detected at an 
early stage. In contrast, cancer of the uterine body is increasing in 
incidence, and rarely detected at the initial stages. While most tumors 
of the uterine body are adenocarcinomas derived from the subintimal 
gland, tumors of the uterine cervix are classified into squamous cancer 
and adenocarcinoma. Smooth muscle tumors (SMTs) which develop 
in the myometrium have been traditionally divided into benign 
leiomyoma (LMA) and malignant leiomyosarcoma (LMS) based on 
cytological atypia, mitotic activity and other criteria. Uterine LMS is 
a rare gynecologic malignancy in the female genital tract, having an 
estimated annual incidence of 0.64 per 100,000 women [1]. Uterine 
LMS accounts for 2% to 5% of tumors of the uterine body and develops 
more often in the muscle layer of the uterine body than in the uterine 
cervix [2,3].
A main factor in the development of tumors in the uterine body is 
the hormonal environment. Patients with uterine body tumors often 
are unmarried, have never been pregnant, and are taking a hormonal 
agent. High estrogen levels are considered to significantly influence the 
development of such tumors. The mechanisms by which uterine LMA 
and LMS develop are not yet clearly understood, though tumors that 
have developed in the myometrium for some reason gradually become 
larger due to the influence of the female hormone, estrogen, and 
generate tumors. However, no correlations between the development 
of uterine LMS and hormonal conditions, and no obvious risk factors 
have been identified. The prognosis of uterine LMS is not good, and 
the five-year survival rate is approximately 35%, although the five-year 
survival rate depends on disease stage [2,3]. It is worth noting that, 
when adjusted for stage and mitotic count, LMS has a significantly 
worse prognosis than carcinosarcoma [4]. As uterine LMS is resistant 
to chemotherapy and radiotherapy, and thus surgical intervention is 
virtually the only means of treatment, developing an efficient adjuvant 
therapy is expected to improve the prognosis of the disease [5-7]. Most 
damaged cells can  initiate tumor. To avert this, faulty cells disable 
their own propagation by undergoing senescence. Fortunately, cells 
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Abstract
The majority of smooth muscle tumors found in the uterus are benign, but uterine leiomyosarcomas (LMSs) 
are extremely malignant, with high rates of recurrence and metastasis. The development of gynecologic tumors 
is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially 
correlated with hormonal conditions, and the risk factors are not clearly understood. The presentation of antigenic 
peptides by major histocompatibility complex (MHC) class I molecules is important for tumor rejection by cytotoxic 
T-lymphocytes (CTLs). Such antigenic peptides are generated as a result of the degradation of intracellular proteins
by the proteasome pathway, a process that is �����?by the interferon (IFN)-γ-inducible low molecular mass
polypeptide-2 (LMP2) subunit of the 20S proteasome. Homozygous �����mice for LMP2 are now known to
spontaneously develop uterine LMS. LMP2 expression is reportedly absent in human uterine LMS, but present in
human myometrium. Further studies revealed a few ������?CD56 + NK cells in human uterine LMS tissues. This
review aims at summarizing recent insights into the regulation of NK cell function and the T cell-mediated immune
��������������������������������������������������������
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can detect their own level of damage and eventually dismiss themselves 
in a final act of altruism for the benefit of the organism. Self-dismissal 
comes in two forms, apoptosis “self-destruction” and senescence “self-
disabling”, with the latter being at least as prominent as the former 
in providing protection against malignant tumors [8,9]. But for full 
protection against malignant tumors, the senescent cells must be cleared 
by the T cell-mediated immune system including NK cells [10,11]. The 
biological characteristic of uterine LMS would significantly contribute 
to the development of preventive and therapeutic treatments.
Proteasomal Function Induced by IFN-γ in MHC Class 
I-Mediated Tumor Rejection
When tissue or an organ is transplanted, the arograft is often lost due 
to an acute rejection caused by the host immune-system. This is because 
the cell surface antigens presented by the major histocompatibility 
complex (MHC) are intrinsic to an individual and so differ between the 
donor and recipient. The immunological self-markers on cell surfaces 
are the most important immune-system for higher vertebrates such as 
mammals, protecting the self from invaders. Cytoplasmic proteins are 
mostly degraded by a protease complex, which has many substrates 
consisting of twenty-eight 20 to 30-kDa subunits, referred as the 
proteasome [12]. The proteasomal degradation pathway is essential 
for many cellular processes, including the cell cycle and the regulation 
of gene expression. Proteasomal degradation pathway is also essential 
for the production of peptide antigens, which are presented by MHC 
class I molecules. The proteasome plays a key role in the presentation 
of immunological self-markers on the cell surface by the MHC [12]. 
IFN-γ up-regulates the expression of large numbers of responsive 
genes, proteasome’s subunits, i.e., low-molecular mass polypeptide 
(LMP) 2, LMP7, and LMP10 are also markedly induced by IFN-γ [13-
16].
The IFN-γ-induced biological function of a reconstructive 
proteasome, called the immuno-proteasome, plays a key role in MHC 
class I-mediated tumor rejection [15,17]. Furthermore, a molecular 
approach to studying the correlation of IFN-γ with tumor cell growth 
has drawn attention. A deficiency of IFN-γ apparently does not hamper 
the generation of cytotoxic T lymphocyte (CTL) [14,15]. Recent 
reports have demonstrated multifunctional deficiencies of components 
of the MHC class I antigen-presentation pathway including LMP2 and 
LMP7 in tumor cells [15,17]. Here we identify LMP2, a single IFN-γ-
responsive gene product, as obligatory for tumor surveillance [16]. 
Defective LMP2 Expression in Uterine LMS 
Malignant tumors originate from a single cancerous cell and develop 
as a result of unlimited cell proliferation. Malignant tumor cells have 
properties that are biologically different from those of normal cells, 
thus, the host immune-system should be able to distinguish malignant 
tumor cells from corresponding normal cells. That is, malignant tumor 
cells present intrinsic antigens as tumor-antigens (TA) on the tumor cell 
surface with the aid of MHC molecules. In many cases, however, almost 
no reaction by the immune-system is observed. Also, the incidence 
of major tumors is not very different between immunodeficient (i.e., 
lymphocyte-deficient) mice and control mice having normal immune-
systems. Specifically, tumor cells can avoid the immune monitoring 
system via several means [10,11,18,19]. Naturally- occurring tumor 
cells seem to have lost the expression of peptide antigens, TA, or cell-
adhesion factors intrinsic to tumors. Tumor cells may avoid the host 
immune reaction due to the absence of MHC expression, although no 
such mechanism has yet been completely elucidated.
The genes encoding LMP2, LMP7, TAP1 and TAP2, are located in 
the region encoding the MHC molecules. The homozygous deficient 
mice for LMP2 show tissue- and substrate- dependent abnormalities in 
the biological functions of the proteasome, and impaired functioning 
of the proteasome in splenocytes or hepatic cells [20]. Furthermore, 
LMP2-deficient mice do not show normal immune responses to virus-
infected cells, and such immunopathy is known to result from a failure 
in the presentation of peptide antigens on the cell surface by the MHC 
[20]. Uterine LMS reportedly occurred in female LMP2-deficient mice 
at age 6 months or older, and the incidence at 14 months of age was 
about 40% [21,22]. The curve indicating the incidence in mice is very 
similar to that indicating the incidence of human uterine LMS, which 
occurs after menopause. Histological studies of LMP2-lacking uterine 
tumors revealed characteristic abnormalities of uterine LMS [21,22]. 
The tumors lacked lymphoid infiltrates, a sign of immune recognition, 
and consisted of uniform elongated myometrium cells arranged 
into bundles. The nuclei of the tumor cells varied in size and shape, 
furthermore, mitosis was frequent, in contrast, the myometrium cells of 
C57BL/6 mice were normal in appearance [21,22]. Whereas relatively 
few Ki-67-positive cells, the proliferating cells of solid tumors, were 
observed in the basal cell layer of the normal myometrium, most of 
the basal cells vividly expressed Ki-67 in LMP2-deficient mice [21,22]. 
LMP2-deficient mice that have developed uterine LMS undergo 
considerable weight loss, and then die by 14 months of age [21]. The 
LMP2-deficient mice also exhibit skeletal muscle metastasis from 
uterine LMS. Therefore it is likely that LMP2-deficient mice with 
uterine LMS died from the mass effect and metastasis. In general, it 
is not easy to distinguish uterine LMA from LMS. However, in mice, 
because of such characteristic pathological findings, significant weight 
loss and skeletal muscle metastasis, a tumor that develops in the 
uterus of an LMP2-deficient mouse can be considered malignant, i.e., 
a uterine LMS. Further experiments demonstrated the loss of LMP2 
expression in human LMS, but detectable LMP2 expression in human 
LMA [22,23]. Therefore defective LMP2 expression is likely to be one 
of the risk factors for the development of human uterine neoplasm, as 
it is in the LMP2-deficient mouse [21-23].
Impaired Tumor-Rejection to Uterine LMS by CTLs
Spontaneously arising tumors are rarely rejected by CTLs [24]. It 
is probable that they lack either distinctive antigenic peptides or the 
adhesion and costimulatory molecules necessary to elicit primary T 
cell-responses. Tumors tend to be genetically unstable and can lose 
their antigens by mutation so that in the event of an immune response, 
more escape mutants might be generated [25]. Several research reports 
indicate functional deficiencies of components of the MHC class I 
antigen pathway, including LMP2 in individual tumor cells [26-29]. 
Recent findings also support a reciprocal and linked derangement in 
the immune response to tumor development [30-33] For instance, 
IFN-γ-insensitive mice that lack either the IFN-γ receptor or Stat1 were 
tested for the role of immune surveillance in tumor cell progression 
[31]. These mice lack the IFN-γ signaling pathway that induces 
antigenic peptide presentation with MHC class I. Indeed, the incidence 
of chemical carcinogen-induced cancer was clearly higher in both types 
of mice than in normal mice [31]. 
The current studies support the idea that LMP2 may also be 
important for cancer target recognition. In this study, LMP2-deficient 
mice revealed that this proteasomal subunit significantly influences 
antigen processing for MHC class I molecule-binding peptides, and 
LMP2-deficient mice have reduced levels of immunological competency 
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by CTLs [34]. The defective antigen presentation associated with 
LMP2-deficiency may therefore promote direct escape from immune 
recognition by CTLs.
Uterine-Specific Features of Natural Killer (NK) Cells
NK cells are lymphocytes of the innate immune system that are 
able to kill various hazardous pathogens and tumors. However, it 
is now widely accepted that NK cells also possess non-destructive 
functions, as has been demonstrated for uterine NK cells. NK cells 
comprise approximately 5-15% of peripheral blood lymphocytes. They 
originate in the bone marrow from CD34+ hematopoietic progenitor 
cells, although recent studies suggest that NK cell development also 
occurs in secondary lymphoid tissues and in the thymus [35-37]. 
NK cells populate different peripheral lymphoid and non-lymphoid 
organs, including lymph nodes, thymus, tonsils, spleen, and uterus 
[37,38]. These innate effecter cells specialize in killing tumor and virally 
infected cells and are able to secrete a variety of cytokines [39,40]. The 
CD56dim CD16+ NK cells, which comprise 90% of the NK population, 
are considered to be more cytotoxic than the CD56bright CD16- NK 
cells, which comprise only 10% of peripheral blood NK cells and are 
the primary source of NK-derived immunoregulatory chemo- and 
cytokines, such as IFN-γ and CXCL8 [41] (Table 1).
The CD56bright CD16- NK cells are considered as the regulatory 
subset and a prominent example of their regulatory role is in the 
uterine mucosa prior to and during pregnancy in the endometrial 
and decidual tissues, respectively (Table 1). Information on receptor/
ligand systems used by NK  cells to specifically detect tumor cells has 
been accumulating rapidly. One of these receptor/ligand systems, the 
NKG2D pathway, has received particular attention, and now serves as 
a paradigm for how the immune system is able to gather information 
about the health status of autologous host cells. It is known that certain 
cytokines, for instance IL-21and IFN-α exert anti-tumor effects raising 
the possibility that some of the beneficial effects are mediated by 
NKG2D. 
In general, in the case of solid malignant tumors, although 
infiltrating lymphocytes can possibly be detected in small tumors or 
pre-malignant tumors at the earliest stage, they are not easy to detect 
in large growing tumors including malignant tumors. In the case of 
uterine LMS, the pathological findings are similar to those for uterine 
LMA or other malignant tumors. The tumor cells then become a pre-
malignant tumor or senescent mass and are swiftly and selectively 
eliminated by immune cells - a fate delivered mainly by the innate arm 
of the immune system (macrophages, neutrophils and natural killer 
cells). Pathological studies have demonstrated immune infiltration 
by CD56+ natural killer (NK) cells, CD163+ macrophages and CD4+ 
or CD8+ T cells. Although LMS usually lacks lymphoid infiltrates 
recognizable on routine histological staining, furthermore histological 
examination revealed a few infiltrating CD56+ NK cells in human 
uterine LMS tissues (Figure 1).
Pre-malignant senescent cells secrete chemo- and cytokines and 
are subject to immune-mediated clearance (designated as ‘senescence 
surveillance’) which depends on an intact T cell-mediated adaptive 
immune response [10,11]. Therefore impaired immune surveillance of 
Cell features and functions
Receptor expression Cytotoxicity and proliferation Effect ormolecule expression Other function
CD3- CD122+ , LY49+, CD16- CD56Hi, CD94 (Hs); 
NKp64+ (Hs/Mm); NK 1.1+, NK 1.2+ and DX5+ (Mm) 
CXCL 8 and CXCL12Hi (Hs); IF N-γ , 
VEGF-A , VEGF-B and PLGE Hi (Mm)
ADCC and cytotoxicty 
decreased (Hs)
Regulate endometrial remodelling, angiogenesis 
and implantation (Hs/Mm); uterine NK cell-derrived 
����������������
ADCC, antibody-dependent cell-mediated cytotoxicity; CXCL, CXC-chemokine ligand; DC, dendric cell; IFN-γ, Interferon-γ; NK, natural killer; PLGF, placental growth factor; 
VEGF-A, vascular endothelial growth factor-A; Hs, indicates evidence found in humans, Mm, indicates evidence found in mice, and Hs/Mm, indicates evidence found in 
both human and mice
Table 1: Unique features of NK cells in Uterus [48-53].





The immunohistochemistry was performed to demonstrate the ������?CD56 + natural killer (NK) cells and CD163+ macrophages; CD4+ T cells or CD8+ T cells. 
Although LMS usually lacks lymphoid ������recognizable on routine histological staining; further histological examination revealed a few ������?CD56 + NK 
cells in human uterine leiomyosarcoma tissues.
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pre-malignant senescent cells results in the development of a malignant 
tumor or carcinomas, thus showing that senescence surveillance is 
important for tumor suppression. Recent study has shown that innate 
immune cells alone are sufficient to mediate the clearance of malignant 
tumors, wherein senescence was triggered by the reactivation of 
endogenous p53 [42]. Although research has demonstrated that the 
abnormal expression of ovarian steroid receptors, p53, Ki-67, mutations 
of p53 and cell cycle regulators including senescence markers are 
frequently associated with uterine LMS, clear scientific evidence of the 
characteristic secretion of chemo- and cytokines from uterine LMS is 
not available [22,43,44]. Furthermore the few infiltrating CD56+ NK 
cells might be attributable to functional deficiencies of the MHC class I 
antigen pathway in human uterine LMS tissues.
Conclusion
LMP2 is reportedly implicated in the invasion of placental 
villi, degradation of the extracellular matrix, immune tolerance, 
tumorigenesis and angiogenesis [22,23,45]. Diverse tumors that lose the 
expression of only one type of MHC class I molecule are able to escape 
a specific CTL response [25,46,47] but selected IFN-γ-inducible genes, 
at least in the murine model, confer target specificity to interrupted 
immune recognition. When a tumor loses the expression of all MHC 
class I molecules, it can no longer be recognized by CTLs, although it 
may become susceptible to the CD56bright  CD16- NK subset [19] (Figure 
2). However, tumors that lose only one MHC class I molecule may be 
able to avoid recognition by specific CTLs while remaining resistant 
to NK cells, conferring a selective advantage (Figure 2). For instance, 
hepatic MHC class II expression appears to be necessary to allow the 
directed killing of pre-malignant hepatocytes as senescence surveillance 
was significantly impaired in mice with liver specific MHC class II 
deficiency [10,11]. The ultimate immune response may depend on 
where and when tumor-specific antigens form [31-33]. The senescence 
surveillance of pre-malignant tumor cells is reportedly orchestrated 
by antigen-specific T cells. In the future, cellular senescence program 
may be induced by reagents or biological materials; the clearance of 
senescent tumor cells is executed by tumor immune surveillance with 
the mounting specific immune responses against antigens expressed in 
induced-senescent cells. Furthermore, use of the senescence program 
to trigger or enhance antigen-specific immune responses will likely 
find broad applications to improve vaccination strategies. 
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